Key result
New oral anticoagulants, including rivaroxaban, apixaban, and dabigatran, offer simplified prevention and treatment strategies for thromboembolic disorders without requiring routine coagulation monitoring.
Why the study?
Do new oral anticoagulants (rivaroxaban, apixaban, dabigatran) offer improved or simplified strategies for the prevention and treatment of thromboembolic disorders compared to traditional anticoagulants?
Do new oral anticoagulants (rivaroxaban, apixaban, dabigatran) offer improved or simplified strategies for the prevention and treatment of thromboembolic disorders compared to traditional anticoagulants?
New oral anticoagulants (rivaroxaban, apixaban, dabigatran) offer simplified, fixed-dose strategies without the need for routine coagulation monitoring for managing thromboembolic disorders in primary care.
No takes yet. Share an insight, caveat, or question.
May support simplified primary-care anticoagulation; leaves open head-to-head RCTs versus traditional agents.
Eraso et al. (2013) conducted a review in Thromboembolic disorders. New oral anticoagulants (rivaroxaban, apixaban, dabigatran etexilate) vs. Traditional anticoagulants was evaluated. New oral anticoagulants, including rivaroxaban, apixaban, and dabigatran, offer simplified prevention and treatment strategies for thromboembolic disorders without requiring routine coagulation monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: